Eton Pharmaceuticals Announces Acquisition of PKU GOLIKE® for Phenylketonuria
March 22, 2024 02:00 ET
|
Eton Pharmaceuticals
PKU GOLIKE® is a commercial ultra-rare disease medical formula complementary to Eton's existing metabolic franchise and specialty call pointTransaction is expected to be accretive to 2024...
Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
March 14, 2024 16:01 ET
|
Eton Pharmaceuticals
Q4 2023 revenue of $7.3 million, representing a 109% increase from Q4 2022, marking the twelfth consecutive quarter of sequential product sales growthFull year 2023 revenues reached $31.6 million with...
Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, March 14, 2024
February 29, 2024 16:01 ET
|
Eton Pharmaceuticals
DEER PARK, Ill., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton” or the "Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing...
Eton Pharmaceuticals Awarded U.S. Patent for Proprietary Hydrocortisone Oral Liquid Formulation
February 21, 2024 06:50 ET
|
Eton Pharmaceuticals
DEER PARK, Ill., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing...
Eton Pharmaceuticals Announces Commercial Availability of Ultra-Rare Disease Product Nitisinone Capsules
February 02, 2024 06:50 ET
|
Eton Pharmaceuticals
-- Eton Cares patient support program offers $0 co-pay to eligible, commercially insured patients* ---- Current Nitisinone market is estimated to exceed $50 million annually ---- Product is now...
Eton Pharmaceuticals Reports Third Quarter 2023 Financial Results
November 09, 2023 16:01 ET
|
Eton Pharmaceuticals
Product sales and royalty revenue of $7.0 million up 118% from Q3 2022, representing the eleventh straight quarter of sequential product sales and royalty revenue growthGenerated $0.9 million in...
Eton Pharmaceuticals to Report Third Quarter 2023 Financial Results on Thursday, November 9, 2023
October 30, 2023 06:50 ET
|
Eton Pharmaceuticals
DEER PARK, Ill., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), an innovative pharmaceutical company focused on developing, acquiring, and commercializing products to...
Eton Pharmaceuticals Announces Acquisition of FDA-Approved Ultra-Rare Disease Product Nitisinone
October 04, 2023 06:50 ET
|
Eton Pharmaceuticals
-- Expect Q1 2024 product launch ---- Nitisinone market estimated to be more than $50 million annually ---- Eton will offer Eton Cares support program to all patients -- DEER PARK, Ill., Oct. 04,...
Eton Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference
August 23, 2023 06:50 ET
|
Eton Pharmaceuticals
DEER PARK, Ill., Aug. 23, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare...
Eton Pharmaceuticals Reports Second Quarter 2023 Financial Results
August 10, 2023 16:01 ET
|
Eton Pharmaceuticals
Total Q2 revenue of $12.0 million and net income of $4.6 millionProduct sales and royalty revenue of $6.5 million up 175% from Q2 2022 and 22% from Q1 2023$21.6 million of cash on handLaunched Betaine...